Carrington Laboratories and Mannatech Renew Manapol(R) Supply Agreement

IRVING, Texas, Dec 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- Carrington Laboratories, Inc., (CARN), a leading research-based biopharmaceutical and consumer products company, today announced the renewal of a raw materials supply agreement with Mannatech, Inc. Under the 12-month renewal agreement, Carrington will continue providing Manapol(R) Powder, its proprietary raw material, for use in Mannatech's nutraceutical products.

Carrington's president and CEO Dr. Carlton E. Turner stated, "Our partnership with Mannatech dates back to 1996 when we signed the initial agreement to supply Manapol(R), an ingredient in Mannatech's core nutraceutical products. The extension of this arrangement further upholds the acceptance of Manapol as a key raw material in the manufacture of health-promoting dietary supplements."

About Mannatech

Based in Coppell, Texas, Mannatech, Inc. (MTEX) is a wellness solutions provider that develops innovative, high quality, proprietary nutritional supplements, topical products and weight management products which are sold through a global network marketing system throughout the United Sates and the international markets of Canada, Australia, the United Kingdom, Japan, New Zealand and South Korea.

About Carrington

Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products under the AloeCeuticals(R) brand and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. The Company's DelSite Biotechnologies subsidiary is developing its propriety GelSite(TM) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 120 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world. For more information, visit

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10Q filed November 12, 2004.

Carrington, Manapol, AloeCeuticals, Hydrapol, GelSite, GelVac and Acemannan Hydrogel are trademarks, registered trademarks or service marks of Carrington Laboratories, Inc., in the United States and other countries. All other trademarks or service marks contained herein are the properties of their respective owners.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.